



US008598219B2

(12) **United States Patent**  
**Calderari et al.**

(10) **Patent No.:** **US 8,598,219 B2**  
(45) **Date of Patent:** **\*Dec. 3, 2013**

(54) **LIQUID PHARMACEUTICAL  
FORMULATIONS OF PALONOSETRON**

(71) Applicants: **Helsinn Healthcare S.A.**, Lugano (CH);  
**Roche Palo Alto LLC**, Palo Alto, CA  
(US); **Simone Macciocchi**, Melide (CH);  
**Giulio Macciocchi**, Breganzona (CH)

(72) Inventors: **Giorgio Calderari**, Rancate (CH);  
**Daniele Bonadeo**, Casalzuigno (IT);  
**Roberta Cannella**, Varese (IT); **Alberto**  
**Macciocchi**, Melide (CH); **Andrew**  
**Mikszal**, Palo Alto, CA (US); **Thomas**  
**Malefyt**, Carmel Valley, CA (US);  
**Kathleen M Lee**, Palo Alto, CA (US);  
**Carmin Panuccio**, Casnate con Bernat  
(IT)

(73) Assignees: **Helsinn Healthcare SA**,  
Lugano/Pazzallo (CH); **Roche Palo Alto**  
**LLC**, Palo Alto, CA (US)

(\*) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-  
claimer.

(21) Appl. No.: **13/901,437**

(22) Filed: **May 23, 2013**

(65) **Prior Publication Data**

US 2013/0261592 A1 Oct. 3, 2013

#### Related U.S. Application Data

(63) Continuation-in-part of application No. 13/087,012,  
filed on Apr. 14, 2011, now Pat. No. 8,518,981, which  
is a continuation of application No. 11/186,311, filed  
on Jul. 21, 2005, now Pat. No. 7,947,724, which is a  
continuation of application No. PCT/EP2004/000888,  
filed on Jan. 30, 2004.

(60) Provisional application No. 60/444,351, filed on Jan.  
30, 2003.

(51) **Int. Cl.**  
**A01N 43/52** (2006.01)

(52) **U.S. Cl.**  
USPC ..... **514/397**

(58) **Field of Classification Search**  
USPC ..... **514/397**  
See application file for complete search history.

(56) **References Cited**

#### U.S. PATENT DOCUMENTS

4,695,578 A 9/1987 Coates et al.  
4,753,789 A 6/1988 Tyers et al.  
4,886,808 A 12/1989 King  
4,906,755 A 3/1990 Gittos  
4,929,632 A 5/1990 Tyers et al.  
4,937,247 A 6/1990 King

5,011,846 A 4/1991 Gittos et al.  
5,034,398 A 7/1991 King  
5,202,333 A 4/1993 Berger et al.  
5,240,954 A 8/1993 Tyers et al.  
5,272,137 A 12/1993 Blase et al.  
5,344,658 A 9/1994 Collin  
5,578,628 A 11/1996 Tyers et al.  
5,578,632 A 11/1996 Tyers et al.  
5,622,720 A 4/1997 Collin  
5,854,270 A 12/1998 Gambhir  
5,922,749 A 7/1999 Tyers et al.  
5,955,488 A 9/1999 Winterborn  
6,063,802 A 5/2000 Winterborn  
6,132,758 A 10/2000 Munayyer et al.  
6,284,749 B1 9/2001 Castillo et al.  
6,287,592 B1 9/2001 Dickinson  
6,294,548 B1 9/2001 James  
6,699,852 B2 3/2004 Robichaud  
7,109,339 B2 9/2006 Lee et al.  
7,947,724 B2 5/2011 Calderari et al.  
7,947,725 B2 5/2011 Calderari et al.  
7,960,424 B2 6/2011 Calderari et al.  
8,518,981 B2 8/2013 Calderari et al.  
2001/0020029 A1 9/2001 James  
2003/0095926 A1 5/2003 Dugger, III

#### FOREIGN PATENT DOCUMENTS

EP 0 512 400 A1 4/1992  
WO WO-03100091 12/2003  
WO WO-2004045615 6/2004  
WO WO-2004067005 8/2004  
WO WO-2004703714 9/2004

#### OTHER PUBLICATIONS

Center for Drug Evaluation and Research (Sep. 2002).  
R. M. Eglén et al., "Pharmacological characterization of RS 25259-  
197, a novel and selective 5-HT<sub>3</sub> receptor antagonist, in vivo," Br. J.  
Pharmacology 114:860-866 (1995).  
Chelly, Jacques et al., Oral RS-25259 Prevents Postoperative Nausea  
and Vomiting Following Laparoscopic Surgery, Anesthesiology,  
1996, vol. 85, No. 3A, p. A21.  
Sorbe, Bengt, 5-HT<sub>3</sub> Receptor Antagonists as Antiemetic Agents in  
Cancer Chemotherapy, extracted from Expert Opinion on Investiga-  
tional Drugs, 1996, vol. 5 No. 4, pp. 389-407.  
Gaster, Laramie M. and King, Frank D., Serotonin 5-HT<sub>3</sub> and 5-HT<sub>4</sub>  
Receptor Antagonists, extracted from Medicinal Research Reviews,  
1997 vol. 17, No. 2, pp. 163-214.  
Tang, Jun et al., "Efficacy of RS-25259, a Novel 5-HT<sub>3</sub> Antagonist,  
In the Prevention of Postoperative Nausea and Vomiting after Major  
Gynecologic Surgery," Anesthesiology, 1997, vol. 85, No. 3 suppl. p.  
A329.  
Tang, Jun et al., The Efficacy of RS-25259, a Long-Acting Selective  
5-HT<sub>3</sub> Receptor Antagonist, for Preventing Postoperative Nausea  
and Vomiting After Hysterectomy Procedures, Anesthesia and Anal-  
gesia, 1998, vol. 87, pp. 462-467.  
Adis R&D Profile, Palonosetron RS 25259 197, Drugs in R&D, Oct.  
1999, vol. 2, No. 4, pp. 251-252.

(Continued)

Primary Examiner — Shirley Gembeh

(74) Attorney, Agent, or Firm — Clark G. Sullivan;  
Troutman Sanders LLP

(57) **ABSTRACT**

The present invention relates to shelf-stable liquid formula-  
tions of palonosetron for reducing chemotherapy and radio-  
therapy induced emesis with palonosetron. The formulations  
are particularly useful in the preparation of intravenous and  
oral liquid medicaments.

**8 Claims, No Drawings**